Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
AI Demand for Nvidia Chips Keeps Rising. New China Restrictions Are Likely Just Noise.
Netflix fan explains how to fix audio on shows
Exxon Sees ‘Promising’ Future for Lithium in Arkansas, CEO Says
Google rolls out a major expansion of its Bard AI chatbot
Asia-Focused Carbon Offsets Registry Launches in Singapore
Italy's privacy regulator looks into online data gathering to train AI
Honor Shows Off the World's Thinnest Book-Style Folding Phone at IFA
SolarEdge Launches New Home Hub and Wave Inverters with Embedded Power Control System (PCS) Aimed at Reducing Installation Costs